-
Express 57% of bladder cancer patients have no recurrence in 12 months, and IL-15 super agonist reaches phase 2/3 clinical endpoint
Time of Update: 2021-11-04
▎ WuXi AppTec content team editor October 19, 2021, ImmunityBio announced that its IL-15 super agonist complex Anktiva (N-803) and BCG vaccine (BCG) combined with In the phase 2/3 clinical trial of NMIBC, the primary end point for the treatment of patients with papilloma subtypes was reached, and 57% of patients reached 12-month disease-free survival (DFS) .
-
Biotech double antibody product BAT7104 obtained clinical trial approval
Time of Update: 2021-11-04
For example, the anti-CD47/PD-L1 bispecific antibody IBI322 independently developed by Innovent has now obtained IND approval from the National Medical Products Administration and the US FDA, and is actively preparing for clinical research around the world .
-
Jinfang Pharmaceutical's TGF-β R1 inhibitor initiates the first global multi-center phase Ib/II clinical study
Time of Update: 2021-11-04
Based on the data of phase I single-drug clinical trials, GFH018 is expected to inhibit the growth of fibroblasts, regulate multiple tumor microenvironments, and increase the response rate of PD-1 inhibitors in the process of combination medication .
-
Compliance of Rucotinib in the treatment of MF patients: an interim analysis of an Italian prospective real world study (ROMEI)
Time of Update: 2021-11-04
More than one third of MF patients have poor compliance with rucotinib treatment for the general population (N=188) analysis showed that 87%, 83%, 78%, and 71% of patients completed the MMAS-8 questionnaire at 4, 8, 12, and 24 weeks, respectively .
-
Can Cordyceps fight cancer?
Time of Update: 2021-11-04
Therefore, although the active ingredients of Cordyceps sinensis can exert anti-cancer effects, it is urgent to solve the problem of local tumor drug concentration .
This study shows that NUC-7738 can overcome the key cancer drug resistance mechanism and produce higher anti-cancer activity than cordycepin .
-
An article to understand the application progress of ADCs, bispecific antibodies and trispecific antibodies targeting BCMA in MM
Time of Update: 2021-11-04
. Table: Bispecific antibodies in clinical development of multiple myeloma Finally, trispecific antibodies are in the pre-clinical development stage, with dual MM surface marker targeting effects, trying to increase the specificity of MM cells .
-
2021 CSCO Professor Qing Xu: A new model for the treatment of malignant mesothelioma-αPD-1-mesoCAR-T cell therapy
Time of Update: 2021-11-04
mesoCAR-T cell therapy Professor Qing Xu: At present, immunotherapy represented by PD-1 antibody is in the center of tumor treatment, but there are still some tumors, including malignant pleural stromal tumors, with relatively low benefit rates.
-
"Nature" is heavy: this diet can limit tumor growth!
Time of Update: 2021-11-04
Image source: Follow-up analysis by 123RF showed that the activity of SCD in the calorie restriction group has decreased, which caused the tumor cells to not obtain unsaturated fatty acids well, so the lipid supply was impaired and the growth rate would slow down .
-
[Early Tumor Screening] ctDNA Methylation Sequencing: The Most Potential Liquid Biopsy Technology Path
Time of Update: 2021-11-04
With the continuous development and improvement of liquid biopsy technologies such as ctDNA methylation sequencing, as a non-invasive and painless screening method, it will be extremely competitive in the field of early tumor screening in the future .
-
How iron death, metabolic reprogramming and immune infiltration are 1+1+1 greater than 3
Time of Update: 2021-11-04
The main purpose of this study is to identify lncRNAs related to iron death through bioinformatics methods, and construct a prognostic model of PDAC patients based on the size and order relationship between iron death-related lncRNAs, and verify the characteristics of immune infiltration, drug sensitivity and other aspects The classification reliability of the model (Figure 1) .
-
STTT Chinese Academy of Medical Sciences Zhu Hongxia/Xu Ningzhi Reveals New Potential Treatment Targets for Colorectal Cancer
Time of Update: 2021-11-04
19) "of tumor-associated macrophages in human colorectal cancer" research paper, this study sorts the CD206+ TAM infiltrated in CRC, and then conducts RNA-seq analysis .
In summary, XBP1 activation in TAM drives the progression of CRC by increasing the expression and secretion of tumor-promoting cytokines and inhibiting macrophage phagocytosis .
-
The "Lancet" sub-published Zhongshan Sixth Hospital's first study on the effectiveness and safety of neoadjuvant immunotherapy for colorectal cancer; Ribociclib's application for listing in China received tumor information
Time of Update: 2021-11-04
(If you need the original text of the literature, you can add the editor WeChat yxj_oncology to get it) Key points: "The Lancet" sub-published Zhongshan Sixth Hospital's first new treatment for colorectal cancer neoadjuvant immunotherapy JAMA sub-publish: Cabozantinib treatment of brain metastasis kidney cells Cancer patients have considerable curative effect and well tolerated Cancer: Robotic surgery may improve the long-term survival rate of hepatocellular carcinoma patients compared to laparoscopic surgery.
-
Researchers achieve accurate and non-invasive diagnosis of early lung cancer lymph node metastasis
Time of Update: 2021-11-04
In response to the above problems, the Gao Xin team, a researcher at the Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, based on previous research foundations, and aimed at the prediction of lung cancer lymph node metastasis, innovatively proposed a multi-scale, multi-task, multi-label classification neural network suitable for medical imaging.
-
"Nature": The reason for the calorie restriction diet to kill cancer cells has been found!
Time of Update: 2021-11-04
Scientists have found that, unlike what we thought before, the inhibition of tumor growth by calorie restriction (CR) is not due to the reduction of blood sugar levels, but due to the lack of lipids, especially unsaturated fatty acids [3] .
-
Laparoscopic and open distal gastrectomy are the same for patients with locally advanced gastric cancer; another phase III clinical trial of an oral drug for breast cancer is successful!
Time of Update: 2021-11-04
(If you need the original text of the literature, you can add the editor WeChat yxj_oncology to obtain) Key points JAMA Surgery: There is no difference in the five-year survival rate of patients with locally advanced gastric cancer through laparoscopic and open distal gastrectomy!
-
One article summarizes the research progress of three major gynecological tumor immunotherapy
Time of Update: 2021-11-04
The KEYNOTE-775 study is a multi-center, open-label, randomized controlled phase III clinical study that compared pembrolizumab combined with lenvatinib with the treatment regimen selected by the doctor (doxorubicin or paclitaxel weekly therapy) for Efficacy and safety of patients with advanced/recurrent endometrial cancer who have received at least first-line platinum-containing drugs in the past .
-
China's first "Chinese Expert Consensus on Lung and Thymus Neuroendocrine Tumors" was released
Time of Update: 2021-11-04
The European Society of Neuroendocrine Tumors (ENETS), the National Comprehensive Cancer Network (NCCN), the European Society of Medical Oncology (ESMO) clinical diagnosis and treatment guidelines and the World Health Organization (WHO) classification standards, formulated China’s first "Chinese Lung and Thymus Nerve Expert consensus on endocrine tumors (hereinafter referred to as the consensus) .
-
"Science" sub-journals suggest that being "gentle" to tumors can actually make them die faster!
Time of Update: 2021-11-03
According to their new research published in Science Signaling, in order to test the applicability of this phenomenon, Professor Michael Yaffe and colleagues processed tumor cells in vitro according to different concentrations of chemotherapeutics, and then proceeded to it.
-
"Doctor, breast cancer surgery has been postponed so much, is it too late?" This analysis clearly answers
Time of Update: 2021-11-03
This meta-analysis aims to evaluate the efficacy of surgery and primary endocrine therapy (PET) in patients with unprogressive, operable invasive breast cancer, and to determine whether patients with PET as the initial treatment can safely complete delayed surgery .
-
Cell: Zhou Dawang/Chen Lanfen's research group jointly published a paper revealing the important mechanism of glycogen accumulation and phase separation driving the initiation of liver cancer
Time of Update: 2021-11-03
This work found that early liver tumor cells use the extracted glucose to synthesize glycogen as energy storage, and inhibit the activity of the Hippo signaling pathway through liquid-liquid separation, thereby driving the occurrence and development of tumors .
